Markets:

Overview

News

Currencies

International

Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

9.570 +0.450 (+4.93%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 15, 2025

Via Benzinga

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

July 15, 2025

iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy

From MiNK Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 15, 2025

Via Benzinga

A Look at MiNK Therapeutics's Upcoming Earnings Report ↗

May 14, 2025

Via Benzinga

Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

July 15, 2025

Via Benzinga

These stocks are moving in today's session ↗

July 14, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 14, 2025

Via Benzinga

Unusual volume stocks in Monday's session ↗

July 14, 2025

Unusual volume stocks in Monday's session

Via Chartmill

Which stocks are moving on Monday? ↗

July 14, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

July 14, 2025

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

July 14, 2025

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

July 14, 2025

Via Benzinga

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

What's going on in today's after hours session ↗

July 11, 2025

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge ↗

July 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? ↗

July 11, 2025

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with...

Via Benzinga

Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings ↗

July 11, 2025

Via Benzinga

Topics Stocks

MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy ↗

July 11, 2025

“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.

Via Stocktwits

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

July 11, 2025

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

June 10, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

June 02, 2025

Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

May 15, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

May 05, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

March 18, 2025

From MiNK Therapeutics

Via GlobeNewswire

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

Earnings Scheduled For March 18, 2025 ↗

March 18, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.